People | July 11, 2022
Piramal Pharma strengthens board by inducting three new board members
The appointments will add to the well-diversified experience that currently exists on the PPL board.
The appointments will add to the well-diversified experience that currently exists on the PPL board.
The combined company will be able to better serve both our global and regional customers with local production
.jpg)
Evonik's six innovation growth fields are: Sustainable nutrition, healthcare solutions, advanced food ingredients, membranes, cosmetic solutions, and additive manufacturing
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
The company has been issued a Form 483 with two observations which the company will address within the stipulated timeline.
This is the 142nd ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing.
Company is investing more than €100 million in the expansion of the Halle site
Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions
Subscribe To Our Newsletter & Stay Updated
